Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'extrapyramidal symptoms' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 114 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Rittmannsberger, H; Wolfl, H
      Pisa syndrome (pleurothotonus) in a polytoxicomanic patient

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    2. Govoni, S; Racchi, M; Masoero, E; Zamboni, M; Ferini-Strambi, L
      Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly

      MOLECULAR PSYCHIATRY
    3. Moritz, S; Andresen, B; Jacobsen, D; Mersmann, K; Wilke, U; Lambert, M; Naber, D; Krausz, M
      Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics

      EUROPEAN PSYCHIATRY
    4. Burns, MJ
      The pharmacology and toxicology of atypical antipsychotic agents

      JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY
    5. Labelle, A; Light, M; Dunbar, F
      Risperidone treatment of outpatients with schizophrenia: No evidence of sex differences in treatment response

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    6. Hussain, N; Flumerfelt, BA; Rajakumar, N
      Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens

      NEUROSCIENCE
    7. Yoshimura, R; Ueda, N; Nakamura, J
      Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms - Preliminary study

      NEUROPSYCHOBIOLOGY
    8. Koutsilieri, E; ter Meulen, V; Riederer, P
      Neurotransmission in HIV associated dementia: a short review

      JOURNAL OF NEURAL TRANSMISSION
    9. Kaneda, Y; Fujii, A; Nagamine, I
      Platelet serotonin concentrations in medicated schizophrenic patients

      PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
    10. Zhang, XY; Zhou, DF; Cao, LY; Zhang, PY; Wu, GY; Shen, YC
      Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    11. Fleischhacker, WW; Lemmens, P; van Baelen, B
      A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database

      PHARMACOPSYCHIATRY
    12. Suenaga, T; Tawara, Y; Goto, S; Kouhata, SI; Kagaya, A; Horiguchi, J; Yamanaka, Y; Yamawaki, S
      Risperidone treatment of neuroleptic-induced tardive extrapyramidal symptoms

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    13. Hale, A; Azorin, JM; Kasper, S; Maier, W; Syvalahti, E; Van der Burght, M; Sloth-Nielsen, M; Wehnert, A
      Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

      INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
    14. Murphy, CA; Feldon, J
      Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance

      BEHAVIOURAL PHARMACOLOGY
    15. Bester, AM; Harvey, BH
      Early suppression of striatal cyclic GMP may pre-determine the induction and severity of chronic haloperidol-induced vacous chewing movements

      METABOLIC BRAIN DISEASE
    16. Mohr, E; Mendis, T; Hildebrand, K; De Deyn, PP
      Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

      MOVEMENT DISORDERS
    17. Miceli, JJ; Wilner, KD; Hansen, RA; Johnson, AC; Apseloff, G; Gerber, N
      Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    18. Berger, JR; Arendt, G
      HIV dementia: the role of the basal ganglia and dopaminergic systems

      JOURNAL OF PSYCHOPHARMACOLOGY
    19. Nath, A; Anderson, C; Jones, M; Maragos, W; Booze, R; Mactutus, C; Bell, J; Hauser, KF; Mattson, M
      Neurotoxicity and dysfunction of dopaminergic systems associated with AIDSdementia

      JOURNAL OF PSYCHOPHARMACOLOGY
    20. Lecrubier, Y
      Is amisulpride an 'atypical' atypical antipsychotic agent?

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    21. Dollfus, S; Ribeyre, JM; Petit, M
      Objective and subjective extrapyramidal side effects in schizophrenia: Their relationships with negative and depressive symptoms

      PSYCHOPATHOLOGY
    22. Kunstler, U; Hohdorf, K; Regenthal, R; Seese, A; Gertz, HJ
      Reduction of handwriting area and D-2 dopamine receptor occupancy in therapy with typical and atypical neuroleptic drugs

      NERVENARZT
    23. Lenert, LA; Ziegler, J; Lee, T; Sommi, R; Mahmoud, R
      Differences in health values among patients, family members, and providersfor outcomes in schizophrenia

      MEDICAL CARE
    24. Matsumoto, RR; Pouw, B
      Correlation between neuroleptic binding to sigma(1) and sigma(2) receptorsand acute dystonic reactions

      EUROPEAN JOURNAL OF PHARMACOLOGY
    25. Jeste, DV; Okamoto, A; Napolitano, J; Kane, JM; Martinez, RA
      Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

      AMERICAN JOURNAL OF PSYCHIATRY
    26. Bottlender, R; Strauss, A; Moller, HJ
      Prevalence and background factors of depression in first admitted schizophrenic patients

      ACTA PSYCHIATRICA SCANDINAVICA
    27. Itoh, K; Mehraein, P; Weis, S
      Neuronal damage of the substantia nigra in HIV-1 infected brains

      ACTA NEUROPATHOLOGICA
    28. Zesiewicz, TA; Gold, M; Chari, G; Hauser, RA
      Current issues in depression in Parkinson's disease

      AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
    29. Kuenstler, U; Juhnhold, U; Knapp, WH; Gertz, HJ
      Positive correlation between reduction of handwriting area and D-2 dopamine receptor occupancy during treatment with neuroleptic drugs

      PSYCHIATRY RESEARCH-NEUROIMAGING
    30. Krausz, M; Moritz, SH; Naber, D; Lambert, M; Andresen, B
      Neuroleptic-induced extrapyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia

      EUROPEAN PSYCHIATRY
    31. Peralta, V; Cuesta, MJ
      Negative, parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited

      SCHIZOPHRENIA RESEARCH
    32. Casey, DE
      Tardive dyskinesia and atypical antipsychotic drugs

      SCHIZOPHRENIA RESEARCH
    33. Irizarry, MC; Ghaemi, SN; Lee-Cherry, ER; Gomez-Isla, T; Binetti, G; Hyman, BT; Growdon, JH
      Risperidone treatment of behavioral disturbances in outpatients with dementia

      JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
    34. Olianas, MC; Maullu, C; Onali, P
      Mixed agonist-antagonist properties of clozapine at different human clonedmuscarinic receptor subtypes expressed in Chinese hamster ovary cells

      NEUROPSYCHOPHARMACOLOGY
    35. Leonard, BE
      Movement disorders and abuse potential of the selective serotonin reuptakeinhibitors

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    36. Lera, G; Zirulnik, J
      Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism

      MOVEMENT DISORDERS
    37. Haggarty, JM; Husni, M; Peat, C; Allain, S
      Atypical neuroleptic malignant syndrome?

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    38. Caligiuri, MP; Lacro, JP; Jeste, DV
      Incidence and predictors of drug-induced parkinsonism in older psychiatricpatients treated with very low doses of neuroleptics

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    39. Apiquian, R; Fresan, A; Ulloa, RE
      Diagnosis and treatment of patients with a first psychotic episode

      SALUD MENTAL
    40. Juncos, JL
      Management of psychotic aspects of Parkinson's disease

      JOURNAL OF CLINICAL PSYCHIATRY
    41. Mamo, DC; Sweet, RA; Keshavan, MS
      Managing antipsychotic-induced parkinsonism

      DRUG SAFETY
    42. De Deyn, PP; Rabheru, K; Rasmussen, A; Bocksberger, JP; Dautzenberg, PLJ; Eriksson, S; Lawlor, BA
      A randomized trial of risperidone, placebo, and haloperidol for behavioralsymptoms of dementia

      NEUROLOGY
    43. Sanger, TM; Lieberman, JA; Tohen, M; Grundy, S; Beasley, C; Tollefson, GD
      Olanzapine versus haloperidol treatment in first-episode psychosis

      AMERICAN JOURNAL OF PSYCHIATRY
    44. Lemmens, P; Brecher, M; Van Baelen, B
      A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms

      ACTA PSYCHIATRICA SCANDINAVICA
    45. GERBER PE; LYND LD
      SELECTIVE SEROTONIN-REUPTAKE INHIBITOR-INDUCED MOVEMENT-DISORDERS

      The Annals of pharmacotherapy
    46. MACKAY FJ; WILTON LV; PEARCE GL; FREEMANTLE SN; MANN RD
      THE SAFETY OF RISPERIDONE - A POSTMARKETING STUDY ON 7684 PATIENTS

      Human psychopharmacology
    47. MIRSATTARI SM; POWER C; NATH A
      PARKINSONISM WITH HIV-INFECTION

      Movement disorders
    48. LEWIS R
      TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN ADOLESCENT SCHIZOPHRENIA - EFFICACY, TOLERABILITY, AND DIFFERENTIAL SENSITIVITY TO EXTRAPYRAMIDAL SYMPTOMS

      Canadian journal of psychiatry
    49. Chouinard, G; Kopala, L; Labelle, A; Beauclair, L; Johnson, SV; Singh, KI
      Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    50. DIMASCIO M; DIGIOVANNI G; DIMATTEO V; PRISCO S; ESPOSITO E
      SELECTIVE SEROTONIN REUPTAKE INHIBITORS REDUCE THE SPONTANEOUS ACTIVITY OF DOPAMINERGIC-NEURONS IN THE VENTRAL TEGMENTAL AREA

      Brain research bulletin
    51. BRODERICK PA; PIERCEY MF
      CLOZAPINE, HALOPERIDOL, AND THE D-4 ANTAGONIST PNU-101387G - IN-VIVO EFFECTS ON MESOCORTICAL, MESOLIMBIC, AND NIGROSTRIATAL DOPAMINE AND SEROTONIN RELEASE

      Journal of neural transmission
    52. MARTIN P; WATERS N; SCHMIDT CJ; CARLSSON A; CARLSSON ML
      RODENT DATA AND GENERAL HYPOTHESIS - ANTIPSYCHOTIC ACTION EXERTED THROUGH 5-HT2A RECEPTOR ANTAGONISM IS DEPENDENT ON INCREASED SEROTONERGICTONE

      Journal of neural transmission
    53. MOLLER HJ; GAGIANO CA; ADDINGTON DE; VONKNORRING L; TORRESPLANK JF; GAUSSARES C
      LONG-TERM TREATMENT OF CHRONIC-SCHIZOPHRENIA WITH RISPERIDONE - AN OPEN-LABEL, MULTICENTER STUDY OF 386 PATIENTS

      International clinical psychopharmacology
    54. NYBERG S; NILSSON U; OKUBO Y; HALLDIN C; FARDE L
      IMPLICATIONS OF BRAIN IMAGING FOR THE MANAGEMENT OF SCHIZOPHRENIA

      International clinical psychopharmacology
    55. KASPER S
      HOW MUCH DO NOVEL ANTIPSYCHOTICS BENEFIT THE PATIENTS

      International clinical psychopharmacology
    56. Kasper, S
      Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    57. DRESEL S; TATSCH K; DAHNE I; MAGER T; SCHERER J; HAHN K
      IODINE-123-IODOBENZAMIDE SPECT ASSESSMENT OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS

      The Journal of nuclear medicine
    58. DeVane, CL
      Differential pharmacology of newer antidepressants

      JOURNAL OF CLINICAL PSYCHIATRY
    59. Procyshyn, RM; Zerjav, S
      Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine

      CLINICAL THERAPEUTICS
    60. Daniel, DG; Wozniak, P; Mack, RJ; McCarthy, BG
      Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia

      PSYCHOPHARMACOLOGY BULLETIN
    61. PEPPE A; STANZIONE P; PIERANTOZZI M; SEMPRINI R; BASSI A; SANTILLI AM; FORMISANO R; PICCOLINO M; BERNARDI G
      DOES PATTERN ELECTRORETINOGRAM SPATIAL TUNING ALTERATION IN PARKINSONS-DISEASE DEPEND ON MOTOR DISTURBANCES OR RETINAL DOPAMINERGIC LOSS

      Electroencephalography and clinical neurophysiology
    62. MELTON ST; KIRKWOOD CK; GHAEMI SN
      PHARMACOTHERAPY OF HIV DEMENTIA

      The Annals of pharmacotherapy
    63. POYUROVSKY M; SCHNEIDMAN M; WEIZMAN A
      SUCCESSFUL TREATMENT OF FLUOXETINE-INDUCED DYSTONIA WITH LOW-DOSE MIANSERIN

      Movement disorders
    64. MANNION L; OSULLIVAN S; CARNEY PA; MORAN J
      PARKINSONS-DISEASE EXACERBATED BY PAROXETINE

      Irish journal of psychological medicine
    65. WARDEN CR; DIEKEMA DS; ROBERTSON WO
      DYSTONIC REACTION ASSOCIATED WITH DEXTROMETHORPHAN INGESTION IN A TODDLER

      Pediatric emergency care
    66. LEHMANN HE; BAN TA
      THE HISTORY OF THE PSYCHOPHARMACOLOGY OF SCHIZOPHRENIA

      Canadian journal of psychiatry
    67. MIYAWAKI E; MEAH Y; KOLLER WC
      SEROTONIN, DOPAMINE, AND MOTOR EFFECTS IN PARKINSONS-DISEASE

      Clinical neuropharmacology
    68. KORF J
      IMAGING OF RECEPTORS IN CLINICAL NEUROSCIENCES

      Acta neurologica belgica
    69. MILLER R
      DOSE-RESPONSE RELATIONSHIPS FOR THE ANTIPSYCHOTIC EFFECTS AND PARKINSONIAN SIDE-EFFECTS OF TYPICAL NEUROLEPTIC DRUGS - PRACTICAL AND THEORETICAL IMPLICATIONS

      Progress in neuro-psychopharmacology & biological psychiatry
    70. FINKEL SI
      MANAGING THE BEHAVIORAL AND PSYCHOLOGICAL SIGNS AND SYMPTOMS OF DEMENTIA

      International clinical psychopharmacology
    71. FREEMAN HL
      AMISULPRIDE COMPARED WITH STANDARD NEUROLEPTICS IN ACUTE EXACERBATIONS OF SCHIZOPHRENIA - 3 EFFICACY STUDIES

      International clinical psychopharmacology
    72. KRAKOWSKI M; CZOBOR P; VOLAVKA J
      EFFECT OF NEUROLEPTIC TREATMENT ON DEPRESSIVE SYMPTOMS IN ACUTE SCHIZOPHRENIC EPISODES

      Psychiatry research
    73. FLEISCHHACKER WW; HUMMER M
      DRUG-TREATMENT OF SCHIZOPHRENIA IN THE 1990S - ACHIEVEMENTS AND FUTURE POSSIBILITIES IN OPTIMIZING OUTCOMES

      Drugs
    74. ABRAHAM JT; BROWN R; MELTZER HY
      CLOZAPINE TREATMENT OF PERSISTENT PAROXYSMAL DYSKINESIA ASSOCIATED WITH CONCOMITANT PAROXETINE AND SUMATRIPTAN USE

      Biological psychiatry
    75. FRIEBOES RM; MURCK H; WIEDEMANN K; HOLSBOER F; STEIGER A
      OPEN CLINICAL-TRIAL ON THE SIGMA-LIGAND PANAMESINE IN PATIENTS WITH SCHIZOPHRENIA

      Psychopharmacology
    76. JESTE DV; KLAUSNER M; BRECHER M; CLYDE C; JONES R; ABUZZAHAB FS; AHMAD A; AHMED S; AINSLIE G; ALIDON G; JAMPALA VC; ANDRIULLI G; ASHLEIGH EA; AUKSTUOLIS J; BACON RJ; BADHIWALA SP; BAGRI KS; BALDWIN JD; BARDINELLI AJ; BARON D; BARTHOLOW G; BEACH RL; BERA RB; BERKEY R; BIRD LJ; BOYER W; ESCALONA R; CACCIOPPOLI G; TALIAFERRO J; CARTER RG; CENTRIC RW; CHARALAMPOUS KD; CHASTEK JW; CHAUHAN N; CHO SN; COHEN AJ; COHN CK; CORDER SL; CUERVO MS; CUTLER MO; DAMERA BR; HAMILTON RS; DANIELS K; DASKALOV Z; DAVID A; DAVIS H; DELEON J; DELLARIO AV; DIRKSEN JS; DOSSANTOS E; DOW TW; DOWNIE D; DRELL WK; EKHOLM C; ELIO E; FABRE L; FALCI T; FISHBEIN JH; FREER JH; FRENKEL D; FULLER W; GERHARDSTEIN R; GRACE J; GREINER T; GUPTA BK; HAMADANI HG; HARTFORD JT; HEGE DL; HICKS PB; HILL WJ; HOLINER J; HOLLAND PJ; HORNE RL; IBE IO; ISHAQUE S; IVORY PB; JACOBSON C; JAMIESON RC; JOHNSON CG; KENNEDY B; KESKINER A; KLING A; KLUGHEIT M; KOHLI AK; KOMARLA AK; LANIER P; LEONE NF; LILES JR; LU TC; MAHFOOZI H; MALEKPOUR B; MALONE DA; MANNAVA P; MANNING DB; MANSCHRECK T; MCLARNON MC; MCMINN MR; MEELEE D; MEGOWEN GL; MEHLER C; MERAYO HE; MIAN MA; MINGIONE DL; MITTAL D; MODIR K; MOON TK; MUNOZ RA; NADEL SM; NAGI K; NALLURI AC; NOORDSIJ AJ; ORELLANA E; PASTERNAK IM; PATEL D; PATWA VK; PETRIE WM; PINSKI G; PUESAN R; QADRI MK; RAFULS WA; RAICHMAN JA; RAMESHWAR ER; RAO TV; REBECK B; STUMPF A; REIST C; RHEW SS; RISBY ED; ROCK NL; ROSENBLATT S; ROSENSTOCK HA; ROSILLO R; ROSSON BA; ROY SK; RUIZ EG; SANCLEMENTE JP; SANDERS RQ; SANDLER NH; SCHLUETER J; SCHOOFF K; SHINDERMAN M; SOLOMON R; SPIVY DF; STEPHENS W; SWE NN; THOMPSON PM; THORNELOE WF; TIRANDAZ H; TUAN CH; TUCKER TA; UNFRIED GJ; VALKO TR; VEITS H; VILLALBA AE; VOLLMER S; WALKER P; WANG GL; WEAVER KE; WEICHBRODT G; WEISE CC; WEISS KJ; WELLSHEAR CC; YAPALATER AR; YERASI B; YOUNG AS; ZAKALA M; ZOBER JM; ZUKOF D
      A CLINICAL-EVALUATION OF RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA - A 10-WEEK, OPEN-LABEL, MULTICENTER TRIAL

      Psychopharmacology
    77. ARYA DK
      IS THE 5-HYDROXYTRYPTAMINE (5-HT) NEUROTRANSMITTER SYSTEM INVOLVED INREGULATION OF EXTRAPYRAMIDAL SYMPTOMS

      Journal of drug development and clinical practice
    78. MCCREADIE RG
      MANAGING THE FIRST-EPISODE OF SCHIZOPHRENIA - THE ROLE OF NEW THERAPIES

      European neuropsychopharmacology
    79. SILVER H; GERAISY N
      ON PRESCRIBING AN ANTIPARKINSONIAN DRUG

      Human psychopharmacology
    80. BHARUCHA KJ; SETHI KD
      COMPLEX MOVEMENT-DISORDERS INDUCED BY FLUOXETINE

      Movement disorders
    81. ZABANI I; VAGHADIA H
      REFRACTORY DYSTONIA DURING PROPOFOL ANESTHESIA IN A PATIENT WITH TORTICOLLIS-DYSTONIA DISORDER

      Canadian journal of anaesthesia
    82. MADY S; WAX P; WANG D; GOETZ C; HADLEY C; LOVE R
      PEDIATRIC CLOZAPINE INTOXICATION

      The American journal of emergency medicine
    83. STOUDEMIRE A
      NEW ANTIDEPRESSANT DRUGS AND THE TREATMENT OF DEPRESSION IN THE MEDICALLY ILL PATIENT

      The Psychiatric clinics of North America
    84. LEO RJ
      MOVEMENT-DISORDERS ASSOCIATED WITH THE SEROTONIN SELECTIVE REUPTAKE INHIBITORS

      The Journal of clinical psychiatry
    85. LIEBERMAN JA; KOREEN AR; CHAKOS M; SHEITMAN B; WOERNER M; ALVIR JMJ; BILDER R
      FACTORS INFLUENCING TREATMENT RESPONSE AND OUTCOME OF FIRST-EPISODE SCHIZOPHRENIA - IMPLICATIONS FOR UNDERSTANDING THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA

      The Journal of clinical psychiatry
    86. MEYER MC; BALDESSARINI RJ; GOFF DC; CENTORRINO F
      CLINICALLY SIGNIFICANT INTERACTIONS OF PSYCHOTROPIC AGENTS WITH ANTIPSYCHOTIC-DRUGS

      Drug safety
    87. GOLDMAN SA
      FDA MEDWATCH REPORT - LITHIUM AND NEUROLEPTICS IN COMBINATION - THE SPECTRUM OF NEUROTOXICITY

      Psychopharmacology bulletin
    88. SIMPSON GM; PI EH
      WHATS HAPPENING TO THE NEUROLEPTIC MALIGNANT SYNDROME

      Psychiatric annals
    89. SALLEE FR; DOUGHERTY D; SETHURAMAN G; VRINDAVANAM N
      PROLACTIN MONITORING OF HALOPERIDOL AND PIMOZIDE TREATMENT IN CHILDREN WITH TOURETTES-SYNDROME

      Biological psychiatry
    90. SALOKANGAS RKR; SAARIJARVI S; TAIMINEN T; KALLIONIEMI H; LEHTO H; NIEMI H; TUOMINEN J; AHOLA V; SYVALAHTI E
      CITALOPRAM AS AN ADJUVANT IN CHRONIC-SCHIZOPHRENIA - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

      Acta psychiatrica Scandinavica
    91. KINON BJ; LIEBERMAN JA
      MECHANISMS OF ACTION OF ATYPICAL ANTIPSYCHOTIC-DRUGS - A CRITICAL ANALYSIS

      Psychopharmacology
    92. KAPUR S
      5-HT2 ANTAGONISM AND EPS BENEFITS - IS THERE A CAUSAL CONNECTION

      Psychopharmacology
    93. VANKAMMEN DP; MCEVOY JP; TARGUM SD; KARDATZKE D; SEBREE TB; ANDORN A; BAKER RW; SCHOOLER NR; BORISON RL; CASEY D; ERESHEFSKY L; FUNDERBERG L; HAMNER M; KARSON C; MARDER S; MCKINNEY W; SMALL JG; TAMMINGA C; TUASON V; VOLAVKA J; CHUNG L
      A RANDOMIZED, CONTROLLED, DOSE-RANGING TRIAL OF SERTINDOLE IN PATIENTS WITH SCHIZOPHRENIA

      Psychopharmacology
    94. INADA T; YAGI G
      CURRENT TOPICS IN TARDIVE-DYSKINESIA IN JAPAN

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    95. GERLACH J; PEACOCK L
      INTOLERANCE TO NEUROLEPTIC DRUGS - THE ART OF AVOIDING EXTRAPYRAMIDALSYNDROMES

      European psychiatry
    96. BUTTERWORTH RF; SPAHR L; FONTAINE S; LAYRARGUES GP
      MANGANESE TOXICITY, DOPAMINERGIC DYSFUNCTION AND HEPATIC-ENCEPHALOPATHY

      Metabolic brain disease
    97. FITZGERALD K; HEALY D
      DYSTONIAS AND DYSKINESIAS OF THE JAW ASSOCIATED WITH THE USE OF SSRIS

      Human psychopharmacology
    98. BERGERON M; SWAIN MS; READER TA; BUTTERWORTH RF
      REGIONAL ALTERATIONS OF DOPAMINE AND ITS METABOLITES IN RAT-BRAIN FOLLOWING PORTACAVAL ANASTOMOSIS

      Neurochemical research
    99. WHITWORTH AB; FLEISCHHACKER WW
      ADVERSE-EFFECTS OF ANTIPSYCHOTIC-DRUGS

      International clinical psychopharmacology
    100. GERLACH J; PEACOCK L
      NEW ANTIPSYCHOTICS - THE PRESENT STATUS

      International clinical psychopharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 14:28:16